Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Kohles, Nikolaus ^a   Nagel, Dorothea ^a   Jüngst, Dietrich ^a   Durner, Jürgen ^a   Stieber, Petra ^a   Holdenrieder, Stefan ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; C REACTIVE PROTEIN; CYTOKERATIN 19 FRAGMENT; EPIRUBICIN; GAMMA GLUTAMYLTRANSFERASE; IODINATED POPPYSEED OIL; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; NUCLEOSOME; OUTCOME ASSESSMENT; PREDICTION; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; BLOOD; KINETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; KINETICS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NUCLEOSOMES; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79957450110     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-202     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001, 94:153-156. 10.1002/ijc.1440, 11668491.
2. El-Serag HB, Mason AC. Hepatocellular carcinoma is rising in the United States. Gastroenterol 1999, 116:G0235.
3. Hellerbrand C, Hartmann A, Richter G, Knoll A, Wiest R, Scholmerich J, Lock G. Hepatocellular carcinoma in southern Germany: Epidemiological and clinicopathological characteristics and risk factors. Digest Dis 2001, 19:345-351.
4. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328:1797-1801. 10.1056/NEJM199306243282501, 7684822.
5. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, Martinez I, Rodrigo L. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatol 2003, 37:520-527.
6. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterol 2008, 134:1752-1763.
7. Forner A, Hessheimer AJ, Real MI, Bruix J. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 2006, 60:89-98. 10.1016/j.critrevonc.2006.06.001, 16860993.
8. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MD, Vilana R, Rodes J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. Hepatol 1998, 27:1578-1583.
9. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatol 2003, 37:429-442.
10. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739. 10.1016/S0140-6736(02)08649-X, 12049862.
11. Anonymous A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med 1995, 332:1256-1261. Anonymous.
12. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, Van Steenbergen W, Buffet C, Rougier P, Adler M, Pignon JP, Roche A. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998, 29:129-134. 10.1016/S0168-8278(98)80187-6, 9696501.
13. Takayasu K, Arii S, Ikao I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterol 2006, 131:461-469.
14. Bruix JSM, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterol 2004, 127:179-188.
15. Lim HS, Jeong YY, Kang HK, Kim JK, Park JG. Imaging features of hepatocellular carcinoma after transcatheter arterial chemoembolization and radiofrequency ablation. Am J Roentgenol 2006, 187:W341-349.
16. Takayasu K, Arii S, Matsuo N, Yoshikawa M, Ryu M, Takasaki K, Sato M, Yamanaka N, Shimamura Y, Ohto M. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. Am J Roentgenol 2000, 175:699-704.
17. Thabet A, Kalva S, Gervais DA. Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response. Abdom Imaging 2009, 34:593-609. 10.1007/s00261-008-9448-9, 19015913.
18. Chen CY, Li CW, Kuo YT, Jaw TS, Wu DK, Jao JC, Hsu JS, Liu GC. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: Choline levels and MR diffusion constants initial experience. Radiol 2006, 239:448-456.
19. Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind JFH. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Intervent Radiol 2006, 17:505-512.
20. Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D, Stieber P. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 2009, 63:128-135. 10.1016/j.lungcan.2008.05.001, 18571761.
21. Holdenrieder S, v Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D, Stieber P. Nucleosomes, ProGRP, NSE, CYFRA 21-1 and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy. Clin Cancer Res 2008, 14:7813-7821. 10.1158/1078-0432.CCR-08-0678, 19047109.
22. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001, 35:421-430. 10.1016/S0168-8278(01)00130-1, 11592607.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
24. Holdenrieder S, Stieber P, Bodenmuller H, Fertig G, Furst H, Schmeller N, Untch M, Seidel D. Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med 2001, 39:596-605. 10.1515/CCLM.2001.095, 11522104.
25. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, Okita K, Omata M, Takayasu K, Yamaoka Y. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004, 101:796-802. 10.1002/cncr.20426, 15305412.
26. Meyn RE, Stephens LC, Ang KK, Hunter NR, Brock WA, Milas L, Peters LJ. Heterogeneity in the development of apoptosis in irradiated murine tumors of different histologies. Int J Radiat Biol 1993, 64:583-591. 10.1080/09553009314551801, 7902398.
27. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009, 15:513-520. 10.3748/wjg.15.513, 2653340, 19195051.
28. Jing Z, Nan KJ, Hu ML. Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma. World J Gastroenterol 2005, 11:1910-1916.
29. Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci 2009, 46:1-24. 10.1080/10408360802485875, 19107649.
30. Kremer A, Wilkowski R, Holdenrieder S, Nagel D, Stieber P, Seidel D. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumor Biol 2005, 26:44-49.
31. Kremer A, Holdenrieder S, Stieber P, Wilkowski R, Nagel D, Seidel D. Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumor Biol 2006, 27:235-242.
32. Beachy SH, Repasky EA. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother 2008, 57:759-775. 10.1007/s00262-007-0445-6, 18188561.